Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.44 |
| ▸ | HTR3B | O95264 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.44 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.44 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20986693 | 0.98 | HTR3E (0.43) | HTR3EHTR3BHTR2BHTR3ATMEM97 | |
| SCHEMBL11253381 | 0.76 | HTR2B (0.45) | HTR3EHTR3BHTR2BHTR3ATMEM97 | |
| SCHEMBL28008727 | 0.74 | HTR3E (0.48) | HTR3EHTR3BHTR2BHTR3ATMEM97 | |
| SCHEMBL28008737 | 0.74 | HTR3E (0.48) | HTR3EHTR3BHTR2BHTR3ATMEM97 | |
| SCHEMBL28009164 | 0.74 | HTR3E (0.48) | HTR3EHTR3BHTR2BHTR3ATMEM97 | |
| Hydrochloric Acid SCHEMBL20986741 | 0.73 | PARP1 (0.37) | HTR3EHTR3BHTR2BHTR3ATMEM97 | |
| Hydrochloric Acid SCHEMBL20986742 | 0.73 | PARP1 (0.37) | HTR3EHTR3BHTR2BHTR3ATMEM97 | |
| SCHEMBL20986847 | 0.72 | PARP1 (0.36) | HTR3EHTR3BHTR2BHTR3ATMEM97 | |
| SCHEMBL20986849 | 0.72 | PARP1 (0.36) | HTR3EHTR3BHTR2BHTR3ATMEM97 | |
| SCHEMBL20986728 | 0.71 | HTR3E (0.46) | HTR3EHTR3BHTR2BHTR3ATMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190152992-A1 | BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ORION CORPORATION (FI) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152992-A1 | BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | TBXA2R, ADRA2C, ADRB2 | HTR3E 329/4885HTR3B 287/4885HTR2B 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.